(1 April 2026) Tianda Pharmaceuticals’ subsidiaries, Tianda Chinese Medicine (China) Ltd. and TDMall (China) Ltd., jointly participated in the 11th China Pharma & Healthcare Conference and Fair (2026 Xiding Conference) held in Huzhou, Zhejiang from 26 to 29 March. The company comprehensively showcased the wide variety and strengths of its medicine and health products, further strengthening its market presence in off-hospital channels.
Image 1: 2026 Xiding Conference was held in the Longemont Convention Center in Huzhou, Zhejiang.
As China’s largest and most efficient trading platform for the off-hospital health products market, this year’s conference was themed “Sell Good Products, Meet Diverse Health Needs”. It brought together over 50,000 industry professionals and more than 1,200 upstream brand enterprises to explore new growth pathways for retail pharmacies and the off-hospital market.
Image 2: The Tianda Pharma team explained the strengths of their products to visitors.
In response to the current trend of increasingly segmented health consumption scenarios and the shift in consumer demand from “disease treatment” to “daily health maintenance,” Tianda Pharma accurately captured the market pulse showcasing not only a rich product portfolio covering pediatrics, chronic disease management, and health products, but also new products including Metformin Empagliflozin Tablets (I), Bisoprolol Amlodipine Tablets from the pharmaceutical line; "Tuokang®" Lingzhi Oral Liquid (“Blue Hat” Health Food), Polygonatum Rhizome Essence, American Ginseng Essence from the health product line; and other new medicine-food homology products. These offerings attracted purchasing managers and agents from chain pharmacies across the country, who engaged in in-depth discussions with the Tianda Pharma team on clinical value, market positioning, and cooperation models.
With the implementation of the “Healthy China” strategy, the off-hospital market has become a core battlefield for the commercialization of innovative medicine and consumer health products. This event participation was not only a successful showcase of Tianda Pharma’s products and brands, but also a valuable opportunity for in-depth dialogue with the industry and precise capture of market trends.
Image 3: Tianda Pharma product portfolio.
Looking ahead, Tianda Pharma will continue to uphold its mission of “Tianda for Health!” optimizing its product matrix driven by innovation and guided by patient needs. The company looks forward to working hand in hand with industry partners to jointly build a diversified health ecosystem, bringing high-quality health products to every family!
About Tianda Pharmaceuticals Limited
Tianda Pharmaceuticals Limited (“Tianda Pharma”, listed on the Hong Kong Stock Exchange, stock code: 00455.HK) implements the following development strategies: development of TCM as its foundation, development of innovative drugs and medical technologies, as well as development of high-quality medical and healthcare services, striving to become a leading pharmaceutical enterprise that sets its footholds in China while seeking to expand its presence worldwide.
Media Enquiries
Tianda Pharmaceuticals Limited
Corporate Communications
Tel: +852 2295 0303
Email: corpcomm@tianda.com